Current problems in cancer. Case reports最新文献

Pirtobrutinib for relapsed Bing–Neel syndrome following long-term covalent BTK inhibitor therapy: A case report 吡托鲁替尼治疗长期共价BTK抑制剂治疗后复发的Bing-Neel综合征：1例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2026-06-01 Epub Date: 2026-05-27 DOI: 10.1016/j.cpccr.2026.100428

Gaja Cvejić Vidali , Tereza Urdih , Gregor Brecl Jakob , Sandra Šućurović , Matjaž Sever

引用次数: 0

T-cell receptor repertoire analysis in a patient with metastatic renal cell carcinoma with sarcomatoid change successfully treated with nivolumab–ipilimumab combination therapy followed by deferred cytoreductive nephrectomy 1例转移性肾细胞癌伴肉瘤样改变患者的t细胞受体库分析，成功接受纳武单抗-伊匹单抗联合治疗，随后进行延迟细胞减减性肾切除术

IF 0.2

Current problems in cancer. Case reports Pub Date : 2026-06-01 Epub Date: 2026-05-27 DOI: 10.1016/j.cpccr.2026.100427

Yoshihiro Ikehata , Masayoshi Nagata , Takuro Kobayashi , Yuki Nagashima , Naoya Nagaya , Yan Lu , Shigeo Horie

引用次数: 0

Primary pulmonary yolk sac tumor: A case report 原发性肺卵黄囊肿瘤1例

IF 0.2

Current problems in cancer. Case reports Pub Date : 2026-03-01 Epub Date: 2026-01-07 DOI: 10.1016/j.cpccr.2026.100405

Atif Saleem Siddiqui

引用次数: 0

Treatment of inoperable painful recurrent basal cell carcinoma by a novel approach 一种新方法治疗不能手术的复发性疼痛基底细胞癌

IF 0.2

Current problems in cancer. Case reports Pub Date : 2026-03-01 Epub Date: 2026-01-03 DOI: 10.1016/j.cpccr.2026.100403

Abolfazl Zanghaei , Ehsan Soltani , Mahdi Razmara , Seyedmajid Mousavijavardi , Daryoush Hamidi Alamdari

引用次数: 0

Panitumumab-induced trichomegaly in a patient with metastatic colorectal cancer: Case report and systematic literature review 帕尼单抗诱导的转移性结直肠癌患者滴虫症1例：病例报告和系统文献综述

IF 0.2

Current problems in cancer. Case reports Pub Date : 2026-03-01 Epub Date: 2025-12-27 DOI: 10.1016/j.cpccr.2025.100402

Enes Erul , Erman Akkus , Fatih Koksal , Abdulhakim Konukman , Arzu Yasar

{"title":"Panitumumab-induced trichomegaly in a patient with metastatic colorectal cancer: Case report and systematic literature review","authors":"Enes Erul , Erman Akkus , Fatih Koksal , Abdulhakim Konukman , Arzu Yasar","doi":"10.1016/j.cpccr.2025.100402","DOIUrl":"10.1016/j.cpccr.2025.100402","url":null,"abstract":"<div><h3>Introduction</h3><div>The advent of targeted therapies, such as panitumumab, has significantly improved treatment outcomes for metastatic colorectal cancer (mCRC). However, these therapies can also induce unique side effects, including trichomegaly, characterized by the abnormal thickening, lengthening, and curling of eyelashes.</div></div><div><h3>Case Report Management & Outcome</h3><div>We report the case of a 67-year-old male with metastatic colorectal cancer who developed trichomegaly following treatment with panitumumab. The patient was initially treated with FOLFOX (fluorouracil, leucovorin, and oxaliplatin) and bevacizumab, but received panitumumab after disease progression. Two months after starting panitumumab therapy, the patient exhibited significant elongation and curling of the eyelashes. Despite the discontinuation of panitumumab due to disease progression, the trichomegaly persisted.</div></div><div><h3>Discussion</h3><div>Panitumumab-induced trichomegaly, while not requiring discontinuation of treatment, can be persistent and may cause discomfort. Awareness and management of this side effect are essential, especially considering its potential impact on patients' quality of life. Future studies are needed to better understand the mechanisms and long-term implications of panitumumab-associated trichomegaly.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"21 ","pages":"Article 100402"},"PeriodicalIF":0.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145979618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Distal femoral central venous catheterization in a semi-sitting position for a patient with lung cancer and superior vena cava syndrome: A case report 半坐位股骨远端中心静脉置管治疗肺癌合并上腔静脉综合征1例

IF 0.2

Current problems in cancer. Case reports Pub Date : 2026-03-01 Epub Date: 2026-02-18 DOI: 10.1016/j.cpccr.2026.100410

Yuji Inagaki , Tomoko Kagawa , Yasushi Inoue , Takashi Nishihara , Takafumi Iguchi , Yoshihiko Taniguchi , Akihiro Tamiya , Kyoichi Okishio

引用次数: 0

A case report of primary malignant melanoma of the cervix 宫颈原发性恶性黑色素瘤1例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2026-03-01 Epub Date: 2026-02-26 DOI: 10.1016/j.cpccr.2026.100412

Ya Liu , Demei Ma , Ping Zhang , Yongxia Yang

引用次数: 0

Unexpected source of massive GI bleed: metastatic renal cell carcinoma and widespread thrombosis – a case report 意外的大量消化道出血来源：转移性肾细胞癌和广泛血栓形成- 1例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2026-03-01 Epub Date: 2025-12-21 DOI: 10.1016/j.cpccr.2025.100401

Abdulmajeed Albarrak

{"title":"Unexpected source of massive GI bleed: metastatic renal cell carcinoma and widespread thrombosis – a case report","authors":"Abdulmajeed Albarrak","doi":"10.1016/j.cpccr.2025.100401","DOIUrl":"10.1016/j.cpccr.2025.100401","url":null,"abstract":"<div><div>Introduction: Upper gastrointestinal bleeding (UGIB) is a potentially life-threatening condition that most commonly arises from peptic ulcers, esophageal varices due to portal hypertension, or mucosal erosions. Variceal bleeding in the absence of liver disease is uncommon and warrants thorough investigation.</div><div>Case Presentation: This case report presents a 56-year-old male who experienced his first episode of hematemesis and melena. Endoscopic evaluation revealed a high-risk bleeding fundal varix, despite no clinical or laboratory evidence of chronic liver disease. Abdominal ultrasound revealed a large left renal mass consistent with renal cell carcinoma, with extensive vascular thromboses involving the portal vein, inferior vena cava, and splenic vein, leading to localized portal hypertension and variceal formation. Despite planned diagnostic and therapeutic interventions, the patient suffered a fatal pulmonary embolism. This case underscores the importance of considering malignancy-related vascular complications in non-cirrhotic variceal bleeding.</div><div>Conclusion: The presentation of UGIB due to isolated gastric varices in a non-cirrhotic patient should prompt evaluation for underlying malignancies, including renal cell carcinoma (RCC). The aggressive vascular invasion characteristic of RCC can lead to significant complications, including portal hypertension and thromboembolic events. Early diagnosis and management are essential to improve patient outcomes.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"21 ","pages":"Article 100401"},"PeriodicalIF":0.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145898085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of STRN-ALK fusion positive lung adenocarcinoma treated with lorlatinib monotherapy 氯拉替尼单药治疗STRN-ALK融合阳性肺腺癌1例

IF 0.2

Current problems in cancer. Case reports Pub Date : 2026-03-01 Epub Date: 2026-02-26 DOI: 10.1016/j.cpccr.2026.100411

Christopher S. Hanna, Shea-Lee Godin, Jacob Jones, Yueming Chang, Nathaniel Robinson

{"title":"A case of STRN-ALK fusion positive lung adenocarcinoma treated with lorlatinib monotherapy","authors":"Christopher S. Hanna, Shea-Lee Godin, Jacob Jones, Yueming Chang, Nathaniel Robinson","doi":"10.1016/j.cpccr.2026.100411","DOIUrl":"10.1016/j.cpccr.2026.100411","url":null,"abstract":"<div><div>Anaplastic lymphoma kinase (ALK) rearrangements occur in 3-5% of non-small cell lung cancer (NSCLC), with the STRN-ALK fusion representing a rare variant with variable responses to ALK tyrosine kinase inhibitors (TKIs). Lorlatinib, a third-generation ALK TKI with broad activity against resistance mutations and superior CNS penetration, has not been previously reported in STRN-ALK fusion-positive NSCLC. We present a 52-year-old male never-smoker who initially complained of back pain and was found to have multiple thoracic lesions on a CT scan of the chest, pleural nodules and a pleural effusion, which was found to be consistent with exudative effusion and adenocarcinoma on cytology. He was diagnosed with stage IV lung adenocarcinoma with signet-ring cell features. Next-generation sequencing of tissue identified a STRN-ALK fusion along with pathogenic ARID1A and KMT2D mutations. The patient was initiated on lorlatinib 100 mg daily as first-line therapy. Treatment was complicated by manageable adverse events, including hyperlipidemia, peripheral neuropathy, first-degree AV block, and lower extremity edema. At nine-month follow-up, PET-CT demonstrated a partial response with resolution of bone metastases and a significant reduction in thoracic lesions. This represents the first reported case of STRN-ALK fusion-positive NSCLC treated with lorlatinib monotherapy, demonstrating the clinical efficacy and tolerability of third-generation ALK inhibition for this rare fusion variant, which has variable responses to earlier-generation TKIs in the literature. These findings support lorlatinib as an effective treatment option for STRN-ALK NSCLC, particularly given its superior CNS penetration, which is particularly relevant for preventing or treating brain metastases in patients with previously identified brain metastases.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"21 ","pages":"Article 100411"},"PeriodicalIF":0.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147397746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acquired hemophilia A caused by colon cancer that resulted in early death after onset:A case report 由结肠癌引起的获得性血友病A发病后早期死亡1例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2026-03-01 Epub Date: 2026-02-07 DOI: 10.1016/j.cpccr.2026.100409

Makoto Saito , Masahiro Ieko , Shinpei Harada , Emi Yokoyama , Minoru Kanaya , Koh Izumiyama , Akio Mori , Masanobu Morioka , Takeshi Kondo

{"title":"Acquired hemophilia A caused by colon cancer that resulted in early death after onset:A case report","authors":"Makoto Saito , Masahiro Ieko , Shinpei Harada , Emi Yokoyama , Minoru Kanaya , Koh Izumiyama , Akio Mori , Masanobu Morioka , Takeshi Kondo","doi":"10.1016/j.cpccr.2026.100409","DOIUrl":"10.1016/j.cpccr.2026.100409","url":null,"abstract":"<div><h3>Introduction</h3><div>Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder that can cause severe hemorrhage in elderly patients. Solid tumors are considered one of the causes of this condition, and we report a case of AHA caused by colon cancer that led to death due to severe bleeding shortly after treatment intervention.</div></div><div><h3>Case Presentation</h3><div>An 89-year-old, elderly male patient presented with significant subcutaneous hemorrhage and recurrent bloody stool. Colonoscopy revealed sigmoid colon cancer, and CT scans suggested metastatic lung cancer. Because the factor VIII inhibitor titer was high at approximately 100 BU/mL, prednisolone and cyclophosphamide were administered immediately after the diagnosis of AHA. While the inhibitor titer subsequently began to decrease, but the factor VIII activity level remained in the 1 % range and did not increase, so the patient's tendency to bleed became more pronounced; the bypassing hemostatic agent, a mixture of factors VIIa and X (Byclot®), was also administered. Despite being administered twice, hemostatic control was insufficient, and bleeding persisted intermittently. Furthermore, respiratory failure due to pulmonary emphysema rapidly worsened, and the patient died approximately 2 weeks after treatment intervention.</div></div><div><h3>Conclusion</h3><div>In all three cases treated at our facility, including this patient, AHA develops after the cancer has progressed, making patients difficult to treat and resulting in a poor prognosis. In the future, it will be necessary to investigate a larger number of AHA patients with underlying solid tumors and consider the optimal treatment for each case.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"21 ","pages":"Article 100409"},"PeriodicalIF":0.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146189485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0